📅 21–24 May | Sydney, Australia
📍 International Convention Centre Sydney
PrecisionLife is proud to have participated in the 16th World Congress on Endometriosis (WCE2025), presenting groundbreaking new insights into the genetic and mechanistic drivers of endometriosis and related chronic women’s health conditions.
In Sydney, we explored how our AI-driven precision medicine and combinatorial analytics platform is delivering new diagnostic, therapeutic and preventative strategies for the millions of women affected by endometriosis and other causes of chronic pelvic pain.
📅 Thursday 22 May, 15:00
📍 Advances in Molecular Characterisation track
👤 Steve Gardner, CEO, PrecisionLife
In this session, our CEO and Co-founder, Steve Gardner presents how combinatorial analytics has identified more than 300 disease signatures associated with endometriosis. These findings have been reproduced across three large global cohorts with diverse ancestries, from UK Biobank, OXEGENE and All of Us.
The results allow us to:
● Stratify patients into mechanistically distinct subgroups
● Predict risk and identify the molecular causes of disease with the development of rapid non-invasive tests
● Treat patients effectively with novel drug repurposing targets and biomarkers to accelerate their development
● Prevent the onset and delay the progression of endometriosis with actively protective biology
Steve shares new insights that are enabling precision medicine strategies to predict, treat, and prevent endometriosis.
PrecisionLife also presents further new findings from our disease studies, with: 'Characterizing the Genetic and Biological Differences between Endometriosis and Adenomyosis' - comparing the genetic architectures of endometriosis and adenomyosis.
Our analysis reveals distinct mechanistic drivers for each condition, including multiple genes shared across both and dozens of novel adenomyosis-associated genes not previously reported in endometriosis GWAS.
This research supports the development of a non-invasive and accurate differential diagnostic tool to enable earlier and more confident triage of pelvic pain patients across overlapping conditions such as endometriosis, adenomyosis, PCOS and IBD.
If you're committed to advancing women's health, we invite you to connect with us.
We welcome conversations with researchers, clinicians, patient advocates and biopharma partners who are working to improve outcomes for women around the world.